Seikagaku (TSE:4548) Debt-to-Asset : 0.01 (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Seikagaku Debt-to-Asset?

Seikagaku's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円335 Mil. Seikagaku's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円59 Mil. Seikagaku's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was 円79,886 Mil. Seikagaku's debt to asset for the quarter that ended in Dec. 2023 was 0.00.

Seikagaku Debt-to-Asset Historical Data

The historical data trend for Seikagaku's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Seikagaku Debt-to-Asset Chart

Seikagaku Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-Asset

Get a 7-Day Free Trial

0.01

Seikagaku Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															0.01	0.01	0.01	0.01	0.01

Competitive Comparison of Seikagaku's Debt-to-Asset

For the Medical Devices subindustry, Seikagaku's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Seikagaku's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Seikagaku's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Seikagaku's Debt-to-Asset falls into.

Seikagaku Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Seikagaku's Debt-to-Asset for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(337	+	52)	/	75625
	=	0.01

Seikagaku's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(335	+	59)	/	79886
	=	0.00

Seikagaku (TSE:4548) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Seikagaku Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Seikagaku's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Seikagaku (TSE:4548) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Seikagaku Corp (TSE:4548) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Marunouchi Center Building 10 Floor, 6-1, Marunouchi 1-chome, Chiyoda-ku, Tokyo, JPN, 100-0005

Website

http://www.seikagaku.co.jp

Seikagaku Corp makes and sells pharmaceuticals and medical devices related to glycoconjugates. The firm operates in two segments: pharmaceutical and LAL. The pharmaceutical segment contributes the majority of revenue. This business sells pharmaceutical products made from hyaluronic acid, a major component of glycoconjugates, as well as medical devices and bulk products. The LAL segment manufactures endotoxin-detecting reagents made from limulus amebocyte lysate that are used to control quality in the pharmaceutical manufacturing process. Seikagaku generates the majority of its sales in Japan.

Seikagaku (TSE:4548) Headlines

No Headlines